VRCA Key Statistics, Chart & Performance
The current stock price of VRCA is 8.31 USD. In the past month the price increased by 23.48%. In the past year, price increased by 18.71%.
VRCA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About VRCA
Company Profile
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Company Info
VERRICA PHARMACEUTICALS INC
44 West Gay Street, Suite 400
West Chester PENNSYLVANIA 19380 US
CEO: Ted White
Employees: 71
Phone: 14844533300
VERRICA PHARMACEUTICALS INC / VRCA FAQ
What does VERRICA PHARMACEUTICALS INC do?
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Can you provide the latest stock price for VERRICA PHARMACEUTICALS INC?
The current stock price of VRCA is 8.31 USD. The price increased by 0.12% in the last trading session.
What is the dividend status of VERRICA PHARMACEUTICALS INC?
VRCA does not pay a dividend.
What is the ChartMill technical and fundamental rating of VRCA stock?
VRCA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of VERRICA PHARMACEUTICALS INC (VRCA)?
VERRICA PHARMACEUTICALS INC (VRCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.41).
What is the market capitalization of VRCA stock?
VERRICA PHARMACEUTICALS INC (VRCA) has a market capitalization of 132.88M USD. This makes VRCA a Micro Cap stock.
What is the next earnings date for VRCA stock?
VERRICA PHARMACEUTICALS INC (VRCA) will report earnings on 2026-03-09, after the market close.
VRCA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VRCA. When comparing the yearly performance of all stocks, VRCA is one of the better performing stocks in the market, outperforming 93.93% of all stocks.
VRCA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VRCA. VRCA may be in some trouble as it scores bad on both profitability and health.
VRCA Financial Highlights
Over the last trailing twelve months VRCA reported a non-GAAP Earnings per Share(EPS) of -3.41. The EPS increased by 81.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.61% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VRCA Forecast & Estimates
12 analysts have analysed VRCA and the average price target is 16.83 USD. This implies a price increase of 102.53% is expected in the next year compared to the current price of 8.31.
For the next year, analysts expect an EPS growth of 91.12% and a revenue growth 325.2% for VRCA